Hereditary Angioedema Latest Advances

Title Not Found

Journal: Arerugi = [Allergy]

Published: April 12, 2026

Hereditary Angioedema.

Journal: Cardiology in review

Published: March 20, 2026

Recurrent bowel angioedema in a patient with C1 esterase inhibitor deficiency.

Journal: BMJ case reports

Published: March 19, 2026

Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis.

Journal: Allergy and asthma proceedings

Published: March 17, 2026

Clinical pathway to identify high-risk patients with hereditary angioedema based on abdominal pain symptoms

Journal: Zhonghua nei ke za zhi

Published: March 16, 2026

Prevalence, clinical characteristics and the burden of disease of the Croatian adult patients with HAE: nationwide survey analysis.

Journal: European annals of allergy and clinical immunology

Published: March 12, 2026

Workplace and Healthcare Stigma in Hereditary Angioedema: Links to Anxiety and Functional Impairment.

Journal: Healthcare (Basel, Switzerland)

Published: February 20, 2026

Rethinking the management of hereditary angioedema.

Journal: Allergy and asthma proceedings

Published: February 16, 2026

"Emerging role of plasma kallikrein inhibitors in preventing hereditary angioedema flares in pregnancy".

Journal: Annals of medicine and surgery (2012)

Published: February 12, 2026

Sebetralstat (Ekterly) for treatment of hereditary angioedema attacks.

Journal: The Medical letter on drugs and therapeutics

Published: February 06, 2026

Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present).

Journal: Expert opinion on therapeutic patents

Published: February 05, 2026

N‑Alkyl and N‑Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors.

Journal: ACS medicinal chemistry letters

Published: February 03, 2026

Hereditary Angioedema Latest Advances

Find the Latest Research About Hereditary Angioedema

Title Not Found

Title Not Found

Hereditary Angioedema.

Hereditary Angioedema.

Recurrent bowel angioedema in a patient with C1 esterase inhibitor deficiency.

Recurrent bowel angioedema in a patient with C1 esterase inhibitor deficiency.

Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis.

Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis.

Clinical pathway to identify high-risk patients with hereditary angioedema based on abdominal pain symptoms

Clinical pathway to identify high-risk patients with hereditary angioedema based on abdominal pain symptoms

Prevalence, clinical characteristics and the burden of disease of the Croatian adult patients with HAE: nationwide survey analysis.

Prevalence, clinical characteristics and the burden of disease of the Croatian adult patients with HAE: nationwide survey analysis.

Workplace and Healthcare Stigma in Hereditary Angioedema: Links to Anxiety and Functional Impairment.

Workplace and Healthcare Stigma in Hereditary Angioedema: Links to Anxiety and Functional Impairment.

Rethinking the management of hereditary angioedema.

Rethinking the management of hereditary angioedema.

"Emerging role of plasma kallikrein inhibitors in preventing hereditary angioedema flares in pregnancy".

"Emerging role of plasma kallikrein inhibitors in preventing hereditary angioedema flares in pregnancy".

Sebetralstat (Ekterly) for treatment of hereditary angioedema attacks.

Sebetralstat (Ekterly) for treatment of hereditary angioedema attacks.

Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present).

Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present).

N‑Alkyl and N‑Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors.

N‑Alkyl and N‑Aryl Aminopyrazole Spirocarbamates: A Two-Pronged Lead Optimization Strategy to Identify Orally Bioavailable Plasma Kallikrein Inhibitors.